INOVIO Announces Positive Preliminary Results from Second Cohort of Phase 1/2 Trial with INO-3107

INOVIO Pharmaceuticals

PLYMOUTH MEETING, PA — INOVIO (NASDAQ: INO) recently announced positive preliminary results from the second cohort of its Phase 1/2 clinical trial evaluating INO-3107 for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) in adults.

In the second cohort of 11 patients who were administered INO-3107 via the exploratory side port needle, 10 of the 11 patients (91%) saw a reduction in surgical interventions in the year following initial treatment, with measurement beginning at Day 0, the start of trial therapy. Of these 10 patients, four did not require surgery. There was a statistically significant median decrease of three surgical interventions when comparing the year following treatment to the year prior. In the year prior to treatment, the number of surgical interventions for these 11 patients ranged between 2 and 8, and the median was 5. INO-3107 was well-tolerated and immunogenic among patients in the second cohort. The safety and efficacy results for the second cohort were consistent with results announced for the first cohort in October 2022.

“These results from the second cohort confirm previous data that show INO-3107 is well-tolerated, immunogenic and has the potential to improve patients’ lives by reducing the need for painful surgery,” said Dr. Jeffrey Skolnik, INOVIO’s Senior Vice President of Clinical Development. “We will continue to engage with regulators regarding our development plans for INO-3107 and look forward to publishing and presenting our findings from the complete data set soon.”

“Many patients with RRP need years of repeated surgeries with no end in sight,” said Dr. Ted Mau, Principal Investigator and laryngologist at University of Texas Southwestern Medical Center. “A treatment that results in fewer surgeries – or even no surgery – would be transformational for patients and their families.”

READ:  Larimar Therapeutics to Participate in the Guggenheim Genomic Medicines and Rare Disease Days

“We are pleased with the results from the second cohort, which are consistent with the positive data from the first cohort,” said INOVIO’s President and Chief Executive Officer, Dr. Jacqueline Shea. “We are focused on advancing our most promising candidates and achieving our broader strategic vision of delivering on the potential of DNA medicines for patients.”

For the latest news on everything happening in Chester County and the surrounding area, be sure to follow MyChesCo on Google News.

Thanks for visiting! Looking for some Chester County pride? We got you covered! Shop our MyChesCo store and show your love for Chester County, Pennsylvania. We got shirts, hats, and more – all with a unique ChesCo flair. Plus, proceeds from each purchase helps support our mission of bringing reliable information and resources to the people of Chester County.